The Hidden Costs of Not Treating ADHD
About this webinar
ADHD360 CEO, Phil Anderton, hosted our recent webinar, ‘The Hidden Costs of Not Treating ADHD: Giving Patients THE Argument to Get the Care They Deserve,’ on Thursday 6 March.
In this session, we explored the key findings from “The ADHD Crisis in the UK – A Call to Action,” a report commissioned by ADHD360 and prepared by Loop Dynamics Group Ltd. The report highlights the huge economic and social costs of untreated ADHD, alongside the life-changing benefits of early diagnosis and treatment.
Key findings include:
- Undiagnosed ADHD costs the UK economy billions through annual household losses of £6,500-£11,200.
- The cost of NHS expenditure treating co-morbid conditions could reach £1.33bn-£5.78bn over a decade.
- For every £1 invested in ADHD diagnosis and treatment, a 16 x ROI could be achieved per patient over 10 years, equating to a total potential saving of £1.92 billion (based on 15,000 patients annually).
If you’d like to raise these issues with your local MP and support better ADHD care in the UK, you can download our template letter below to make your voice heard.
ADHD360 mobile & desktop App
Keep yourself and your clinical team up to date with your ADHD symptoms and includes many useful tools.
Key Takeaways
- ✓ Significant Economic Burden vs. Cost Savings: Undiagnosed ADHD carries an estimated total economic cost of £6.5 billion to £11.2 billion (with healthcare costs accounting for £1.3 billion to £5.78 billion). Early intervention and treatment yield a strong Return on Investment (ROI), saving £4 to £6 for every £1 spent over three years, with potential savings reaching up to 16 times the initial investment over ten years.
- ✓ Complex Health & Co-morbidity Impacts: Untreated ADHD extends far beyond core cognitive symptoms, significantly increasing the risk of secondary mental health crises, substance misuse, cardiovascular issues, and type 2 diabetes driven by chronic stress and dopamine-seeking eating behaviors.
- ✓ Systemic Healthcare & Pathway Inefficiencies: Current NHS pathways bottleneck secondary care mental health services. Routing non-crisis ADHD assessments through secondary care increases waiting lists (over 196,000 people currently waiting) and delays essential preventive care.
- ✓ Workplace Productivity & Reasonable Adjustments: ADHD presentation varies widely beyond traditional stereotypes. Tailored workplace accommodations—such as flexible working arrangements, quiet workspace pods, and inclusive management practices—significantly enhance employee retention, reduce burnout, and increase overall workplace productivity.
- ✓ Advocacy & Patient Rights: Patients in England retain the legal Right to Choose their healthcare provider for NHS-funded assessments. Supporting policy expansion and early screening in primary care and education prevents long-term economic and social fallout.
Webinar Transcript
Introduction and Speaker Backgrounds
Phil Anderton: Good evening, everyone, and welcome to our webinar. My name is Phil Anderton, CEO of ADHD 360. Tonight, I am joined by Natasha Scott, an experienced healthcare researcher and consultant. Natasha, would you like to introduce yourself?
Natasha Scott: Thank you, Phil. I am delighted to be here. My background spans 20 years in healthcare within the NHS, moving from general management into strategic transformation and system convenor roles in mental health across Integrated Care Boards (ICBs). Academically, I gained my Master’s degree and professional qualifications while working in the NHS, focusing on executive and ADHD coaching. On a personal level, I am a mother, a wife, and a late-diagnosed female with ADHD. My lived experience, combined with my clinical and operational background in healthcare systems, drives my passion for building inclusive healthcare environments and coaching neurodivergent leaders.
The Motivation Behind the Research
Phil Anderton: As someone with lived experience who has navigated a successful career while managing undiagnosed ADHD, you understand these challenges firsthand. Together, we commissioned research on the hidden costs of untreated ADHD to generate robust UK-based data. Our goal was to provide concrete evidence countering arguments that assessing and treating ADHD is too expensive or unnecessary. How did you find conducting this study?
Natasha Scott: I thoroughly enjoyed working on this project. Having spent two decades in the NHS, I have seen how services often struggle to accommodate neurodivergent needs. There remains considerable stigma, fear, and misunderstanding around ADHD and autism. A major hurdle within the NHS is data collection; without comprehensive data, capturing the true scale of the issue is difficult. Through qualitative case studies with five individuals, clear themes emerged regarding the real daily struggles of undiagnosed ADHD. These experiences highlight that the ongoing challenge for individuals with ADHD is profound and requires formal recognition and clinical support.
The Economic Impact and Return on Investment (ROI)
Phil Anderton: Let us examine the economic figures established in the research paper. What do the numbers tell us about the total financial impact of untreated ADHD?
Natasha Scott: The total economic cost of undiagnosed ADHD is estimated between £6.5 billion and £11.2 billion. The direct healthcare portion alone ranges from £1.3 billion to £5.78 billion. The remaining costs stem from co-occurring mental health conditions, social care requirements, educational disruptions, lost workplace productivity, and criminal justice expenditures. When evaluating the cost-effectiveness of treatment, assessing, diagnosing, and treating one individual over a three-year period costs approximately £7,800. For an cohort of 15,000 people annually (costing around £117 million), the return on investment (ROI) is £4 to £6 returned for every £1 spent over three years. Over a ten-year horizon, treatment can yield up to 16 times the initial investment, generating up to £1.92 billion in potential savings. With at least 196,000 individuals on waiting lists and an estimated 2.25 million adults living with ADHD in the population, doing nothing is economically unsustainable.
Challenging Stigma and Primary Care Barriers
Phil Anderton: When patients request an assessment, primary care providers sometimes hesitate due to perceived costs. How can patients and clinicians use this research during consultations?
Natasha Scott: Clinicians and patients can emphasize that withholding treatment carries a far higher long-term cost than delivering timely care. Many patients face dismissal because they do not fit the historical stereotype of a hyperactive schoolboy. Presentation in females and adults often manifests differently, leading to late diagnosis or misdiagnosis. Primary care professionals operate under severe resource constraints, but dismissing symptoms compounds mental health struggles. Providing accurate screening tools and clinical education helps GPs recognize diverse presentations and refer patients effectively.
Redesigning Healthcare Pathways and Crisis Prevention
Phil Anderton: How does treating ADHD effectively reduce broader secondary healthcare costs?
Natasha Scott: Untreated ADHD leads to repeated presentations for non-responsive depression, anxiety, emergency department visits, and chronic conditions. Addressing ADHD directly reduces reliance on secondary psychiatric care and crisis management services. Currently, patients seeking an ADHD assessment are frequently funneled into traditional secondary mental health waiting lists alongside acute psychiatric crisis cases. This creates severe bottlenecks. Shifting care upstream into community-based, specialized assessment pathways reduces inefficiencies and delivers support before crises occur.
Physical Health Co-morbidities (“ADHD Below the Neck”)
Phil Anderton: Beyond mental health, there is a clear connection between ADHD and physical health conditions, often referred to as “ADHD below the neck.” What did the research highlight regarding physical well-being?
Natasha Scott: Executive dysfunction makes executive planning, routine maintenance, and dietary management difficult. Impulsive dopamine-seeking behaviors frequently lead to reliance on high-sugar or ultra-processed convenience foods, increasing the risk of obesity, type 2 diabetes, and cardiovascular issues. When ADHD is appropriately managed through medication, coaching, or therapy, individuals report improved capacity to establish healthy daily routines, maintain physical exercise, and manage long-term health self-care effectively.
Workplace Challenges, Self-Employment, and Accommodations
Phil Anderton: The case studies in the paper describe career inconsistency and workplace friction. How does treatment affect professional stability?
Natasha Scott: Undiagnosed ADHD can lead to workplace misunderstandings, burnout, rejection sensitivity, and conflict due to differing working styles. Many individuals excel in interest-driven environments but struggle with administrative overhead or rigid structures. Proper diagnosis and treatment restore confidence and focus. Many individuals thrive after securing reasonable adjustments—such as flexible working, quiet workspace pods, or clear written instructions. Others find success in entrepreneurship and self-employment, where interest-driven focus becomes a major strength.
Policy Reform and Strategic Recommendations
Phil Anderton: What systemic changes are necessary to address the ADHD care backlog across the UK?
Natasha Scott: First, patients in England should be supported in exercising their legal Right to Choose an approved NHS-funded provider to reduce wait times. Proposed caps on provider funding risk exacerbating delays and pushing patients out of needed care. Second, commissioners must view ADHD services as an investment rather than an administrative expense. Cross-departmental collaboration across health, education, social care, and justice is essential to build sustainable, integrated pathways. Early screening in schools and primary care will prevent costly long-term complications and enable individuals with ADHD to thrive.